The rise in a variety of genetic abnormalities and infectious diseases is also influencing viral vector generation. For example, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) Statistics, at the end of 2020, 27.5 million [26.5 million – 27.7 million] people worldwide were living with HIV, and 1.5 million (1.0 million – 2.0 million) individuals became newly infected with HIV. 87 percent of those living with HIV were aware of their HIV status and were receiving antiretroviral therapy, with 90 percent of those on the treatment being virally suppressed.
Global viral vector purification market is expected to reach USD 1,401.29 million by 2028 from USD 486.45 million in 2020, growing with a healthy CAGR of 14.2% in the forecast period of 2021 to 2028. Increasing demand for advanced medical technologies for diagnostic and treatment purposes and the rising healthcare expenditure and government support and the rising number of chronic diseases are some of the drivers boosting the growth of the market. Rising geriatric population base, increasing awareness about the availability of treatment options in the developing economies and rising personal disposable income are some other important market growth determinants.
Rise in the demand for viral vectors globally is expected to drive the market's growth rate
The introduction of innovative therapies such as gene therapy, which uses various viral and non-viral vectors to treat a variety of heritable and acquired diseases that previously lacked effective treatment options, has paved the way for the treatment of many heritable and acquired diseases that lacked effective treatment options. This in turn will act as an important market growth determinant. Increased expenditure by public and private players on the development of healthcare infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced healthcare technologies will yet again widen the scope of growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2012 - 2017)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product & Services (Products and Services), Type (Retroviral Vectors, Vaccine Virus, Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentivirus and Other), Workflow (Upstream Processing and Downstream Processing), Purification Technique (Density-Gradient Ultracentrifugation, Ultrafiltration, Precipitation, Two-Phase Extraction Systems and Chromatography), Scale of Operation (Preclinical / Clinical and Commercial), Delivery Method (In Vivo and Ex Vivo), Disease Indication (Cancer, Genetic Disorders, Infectious Diseases, Veterinary Disease and Other), Application (Antisense & RNAi, Gene Therapy, Cell Therapy and Vaccinology), End User (Biotechnology Companies, Pharmaceutical Companies, Contract Research Organizations, Contract Development and Manufacturing Organization (CDMO) and Academic/ Research Institutes)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Applied Biological Materials Inc. (Canada), Creative Biolabs (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Sirion-Biotech GmbH (Germany), Merck KGaA (Gemrany), FUJIFILM Diosynth Biotechnologies (U.S.), Batavia Biosciences B.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Addgene (U.S.), IDT Biologika GmbH (Germany), ProBioGen AG (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (U.S.), Waisman Biomanufacturing (U.S.), Creative Biogene (U.S.), Aldevron (U.S.), uniQure N.V. (Netherlands), BioVision Inc. (U.S.), Cytiva (U.S.) and BIA Separations (Solvenia) among others.
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global viral vector purification market is categorized into nine notable segments which are based on the product & services, purification technique, type, workflow, scale of operation, delivery method, disease indication, application and end user.
- On the basis of product & services, global viral vector purification market is segmented into products and services. In 2021, products segment is expected to dominate the market with 74.95% market share due to availability of diverse range of innovative solutions for vector purification.
- On the basis of type, global viral vector purification market is segmented into retroviral vectors, vaccine virus, adenoviral vectors, adeno-associated viral vectors, lentivirus and other. In 2021, the adeno-associated viral vectors segment is expected to dominate the market with 49.59% market share due to the broad range of AAV infectivity.
- On the basis of workflow, global viral vector purification market is segmented into upstream processing and downstream processing. In 2021, the upstream processing segment is expected to dominate the market with 88.15% market share. The viral vectors produced using this process can be harvested from cells in a short window of time post transfection.
- On the basis of purification technique, global viral vector purification market is segmented into density-gradient ultracentrifugation, ultrafiltration, precipitation, two-phase extraction systems and chromatography. In 2021, the chromatography segment is expected to dominate the market with 44.06% market share because it has been widely used to purify vaccines and gene therapy vectors.
- On the basis of scale of operation, global viral vector purification market is segmented into preclinical / clinical and commercial. In 2021, preclinical / clinical segment is expected to dominate the market with 57.99% market share due to rising investment for research and development activities by major healthcare organizations.
- On the basis of delivery method, global viral vector purification market is segmented into in vivo and ex vivo. In 2021, in vivo segment is expected to dominate the market with 63.05% market share due to its high availability and process reliability.
- On the basis of disease indication, global viral vector purification market is segmented into cancer, genetic disorders, infectious diseases, veterinary disease and other. In 2021, genetic disorders segment is expected to dominate the market with 52.25% market share owing to the rising incidence and prevalence of genetic disorders.
- On the basis of application, global viral vector purification market is segmented into antisense & RNAi, gene therapy, cell therapy and vaccinology. In 2021, gene therapy segment is expected to dominate the market with 48.45% market share due to broad range of applications in medical sector.
- On the basis of end user, global viral vector purification market is segmented into biotechnology companies, pharmaceutical companies, contract research organizations, contract development and manufacturing organization (CDMO) and academic/ research institutes. In 2021, academic/ research institutes segment is expected to dominate the market with 44.33% market share due to increasing initiative activities by various healthcare organizations and government bodies to encourage research endeavor.
Academic/ research institutes dominates the end-user segment of the viral vector purification market
In 2021, academic/ research institutes segment will emerge as the dominating segment with 44.3% market share. This is because of the cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. Also, growth in the number of academic and research facilities will yet again bolster the growth and dominance of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the major viral vector purification market players in advanced wound care market are Applied Biological Materials Inc. (Canada), Creative Biolabs (U.S.), Addgene (U.S.), IDT Biologika GmbH (Germany), ProBioGen AG (Germany), Takara Bio Inc. (Japan), Waisman Biomanufacturing (U.S.), Creative Biogene (U.S.) and uniQure N.V. (Netherlands).
Market Development –
- In January 2021, Aldevron announced expanding its product portfolio with the addition of rep/cap plasmids pALD-AAV2, AAV5 and AAV6 to support the AAV viral vector manufacturing. This new product launched by the company has increased its demand and sales in the market leading to increased revenue in future.
- In September 2020, Waisman Biomanufacturing underwent strategic partnership with the California-based biotech company GigaGen in order to develop a new drug to treat and prevent COVID-19. This strategic partnership done by the company will increase the use of development and testing of new types of drugs by the Waisman Biomanufacturing leading to increased awareness of its services in the market.
Regional Analysis
Geographically, the countries covered in the viral vector purification market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in viral vector purification market during the forecast period 2021 - 2028
North America is dominating the global viral vector purification market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period because of growing healthcare expenditure and well-established healthcare infrastructure for the pharmaceutical/bulk drug intermediates segment. There are many centers and institutes dedicated to advanced therapy research and development. The federal government's investments in expanding the region's cell therapy research base are expected to boost the North American market's growth. The U.S is dominating in North American market due to rise in use of medical devices and increasing awareness towards their health. Also, existence of advanced healthcare technologies in this region is another reason for this region's dominance in the global market.
Asia-Pacific is estimated to be the fastest-growing region in viral vector purification market the forecast period 2021 - 2028
Asia-Pacific is expected to grow during the forecast period due to the increasing patient population and rapid development of infrastructural facilities in emerging economies in this region. In addition to this, rising private and public expenditure on the development of healthcare industry infrastructure in the developing and backward economies and increasing per-capita income are expected to propel the market's growth rate in this region. Also, the increasing geriatric population base, surging incidence rate of chronic and acute disorders and diseases, and rising medical tourism are important market growth determinants.
COVID-19 Impact Analysis
The pandemic of COVID-19 has highlighted the need of vaccine development for the global population, and it has boosted the viral vector manufacturing sector. There are at least 17 vaccinations in use, according to the World Health Organization's (WHO) Global COVID-19 Vaccination - Strategic Vision for 2022. 5.4 billion doses had been provided as of September 6, 2021, with another 300 vaccine candidates in clinical and preclinical development. According to the Infectious Diseases Society of America's Viral Vector Vaccines section, two viral vector vaccines have been approved for emergency use in numerous countries for the COVID-19 vaccine as of January 7, 2022.
For more detailed information about the viral vector purification market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-viral-vector-purification-market
